Cosmetic cross-reference Noindex: medium evidence

552-30-7

CAS 552-30-7

552-30-7 (CAS 552-30-7) is a pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
2
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
552-30-7
CAS Number
552-30-7
UNII
80T61EUU7H
InChIKey
SRPWOOOHEPICQU-UHFFFAOYSA-N
ChEMBL ID
CHEMBL2137687
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 2 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 46242.25 nM 2 -
- MIC 1000 ug.mL-1 1 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 552-30-7 used for in pharmaceutical contexts?

552-30-7 (CAS 552-30-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 552-30-7?

No adverse-event association or SIDER side-effect rows are rendered for 552-30-7 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 552-30-7 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for TRIMELLITIC ANHYDRIDE with EU status "permitted".

What clinical phase is 552-30-7 in?

No phase 1-4 clinical development badge is rendered for 552-30-7 because the matched compound identifier rows do not contain a max-phase value.